
Sign up to save your podcasts
Or
Christopher Bunick, MD, PhD, LiVDerm faculty and member of the SBS Planning Committee, shares key takeaways from his session at the SBS 2022 event regarding IL-13 inhibitors for treatment of AD and the underlying disease pathogenesis.
5
66 ratings
Christopher Bunick, MD, PhD, LiVDerm faculty and member of the SBS Planning Committee, shares key takeaways from his session at the SBS 2022 event regarding IL-13 inhibitors for treatment of AD and the underlying disease pathogenesis.
131 Listeners
25,583 Listeners
111,917 Listeners
1,124 Listeners
18 Listeners
7,953 Listeners
185 Listeners
35 Listeners
134 Listeners
28,473 Listeners
47 Listeners
4 Listeners
82 Listeners
4 Listeners
27 Listeners